 In England and Wales, the National Institute for Health and Care Excellence recommended against dasatinib because of the high cost-benefit ratio.The Union for Affordable Cancer Treatment said that "the dasatinib dispute illustrates the shortcomings of US trade policy and its impact on cancer patients"

The usual dosage for chronic myelogenous leukemia (chronic phase) is 100 mg orally once a day.A daily dose of 100 mg is also used for Philadelphia chromosome-positive acute lymphoblastic leukaemia.